These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 14499416)

  • 1. The contributions of suggestion, desire, and expectation to placebo effects in irritable bowel syndrome patients. An empirical investigation.
    Vase L; Robinson ME; Verne GN; Price DD
    Pain; 2003 Sep; 105(1-2):17-25. PubMed ID: 14499416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of visceral and cutaneous hyperalgesia by local rectal anesthesia in irritable bowel syndrome (IBS) patients.
    Verne GN; Robinson ME; Vase L; Price DD
    Pain; 2003 Sep; 105(1-2):223-30. PubMed ID: 14499439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased placebo analgesia over time in irritable bowel syndrome (IBS) patients is associated with desire and expectation but not endogenous opioid mechanisms.
    Vase L; Robinson ME; Verne NG; Price DD
    Pain; 2005 Jun; 115(3):338-347. PubMed ID: 15911161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced affect/cognition-related brain responses during visceral placebo analgesia in irritable bowel syndrome patients.
    Lee HF; Hsieh JC; Lu CL; Yeh TC; Tu CH; Cheng CM; Niddam DM; Lin HC; Lee FY; Chang FY
    Pain; 2012 Jun; 153(6):1301-1310. PubMed ID: 22541443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrarectal lidocaine is an effective treatment for abdominal pain associated with diarrhea-predominant irritable bowel syndrome.
    Verne GN; Sen A; Price DD
    J Pain; 2005 Aug; 6(8):493-6. PubMed ID: 16084463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism.
    Zighelboim J; Talley NJ; Phillips SF; Harmsen WS; Zinsmeister AR
    Dig Dis Sci; 1995 Apr; 40(4):819-27. PubMed ID: 7720476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irritable bowel syndrome patients show altered sensitivity to exogenous opioids.
    Lembo T; Naliboff BD; Matin K; Munakata J; Parker RA; Gracely RH; Mayer EA
    Pain; 2000 Aug; 87(2):137-147. PubMed ID: 10924807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypersensitivity to visceral and cutaneous pain in the irritable bowel syndrome.
    Verne NG; Robinson ME; Price DD
    Pain; 2001 Jul; 93(1):7-14. PubMed ID: 11406333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing the placebo response: functional magnetic resonance imaging evidence of memory and semantic processing in placebo analgesia.
    Craggs JG; Price DD; Robinson ME
    J Pain; 2014 Apr; 15(4):435-46. PubMed ID: 24412799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expectations and positive emotional feelings accompany reductions in ongoing and evoked neuropathic pain following placebo interventions.
    Petersen GL; Finnerup NB; Grosen K; Pilegaard HK; Tracey I; Benedetti F; Price DD; Jensen TS; Vase L
    Pain; 2014 Dec; 155(12):2687-2698. PubMed ID: 25281929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central representation of visceral and cutaneous hypersensitivity in the irritable bowel syndrome.
    Verne GN; Himes NC; Robinson ME; Gopinath KS; Briggs RW; Crosson B; Price DD
    Pain; 2003 May; 103(1-2):99-110. PubMed ID: 12749964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Placebo analgesia and nocebo hyperalgesia in patients with Alzheimer disease and healthy participants.
    Matthiesen ST; Sieg M; Andersen SS; Amanzio M; Finnerup NB; Jensen TS; Gottrup H; Vase L
    Pain; 2024 Feb; 165(2):440-449. PubMed ID: 37703397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Placebo analgesia is accompanied by large reductions in pain-related brain activity in irritable bowel syndrome patients.
    Price DD; Craggs J; Verne GN; Perlstein WM; Robinson ME
    Pain; 2007 Jan; 127(1-2):63-72. PubMed ID: 16963184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The contribution of suggestibility and expectation to placebo analgesia phenomenon in an experimental setting.
    De Pascalis V; Chiaradia C; Carotenuto E
    Pain; 2002 Apr; 96(3):393-402. PubMed ID: 11973014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Widespread hyperalgesia in irritable bowel syndrome is dynamically maintained by tonic visceral impulse input and placebo/nocebo factors: evidence from human psychophysics, animal models, and neuroimaging.
    Price DD; Craggs JG; Zhou Q; Verne GN; Perlstein WM; Robinson ME
    Neuroimage; 2009 Sep; 47(3):995-1001. PubMed ID: 19375508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional connectivity of the default mode network and its association with pain networks in irritable bowel patients assessed via lidocaine treatment.
    Letzen JE; Craggs JG; Perlstein WM; Price DD; Robinson ME
    J Pain; 2013 Oct; 14(10):1077-87. PubMed ID: 23743257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of learning in nocebo and placebo effects.
    Colloca L; Sigaudo M; Benedetti F
    Pain; 2008 May; 136(1-2):211-8. PubMed ID: 18372113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analgesic and anti-hyperalgesic effects of muscle injections with lidocaine or saline in patients with fibromyalgia syndrome.
    Staud R; Weyl EE; Bartley E; Price DD; Robinson ME
    Eur J Pain; 2014 Jul; 18(6):803-12. PubMed ID: 24193993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for two distinct perceptual alterations in irritable bowel syndrome.
    Naliboff BD; Munakata J; Fullerton S; Gracely RH; Kodner A; Harraf F; Mayer EA
    Gut; 1997 Oct; 41(4):505-12. PubMed ID: 9391250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for autonomic dysregulation in the irritable bowel syndrome.
    Gupta V; Sheffield D; Verne GN
    Dig Dis Sci; 2002 Aug; 47(8):1716-22. PubMed ID: 12184520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.